GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study aims to find best way to stop arthritis drug without relapse
Disease control OngoingThis study looks at 120 people with giant cell arteritis (a type of blood vessel inflammation) who are stable on tocilizumab. Researchers want to see if gradually reducing the drug is better than stopping it all at once to prevent the disease from flaring up. The goal is to find …
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Head-to-Head: can a cheaper drug match a biologic for artery disease?
Disease control OngoingThis study compares two treatments—methotrexate (a common, low-cost drug) and tocilizumab (a newer, expensive biologic)—for giant cell arteritis, a blood vessel disease that can cause headaches, vision loss, and stroke. The goal is to see if methotrexate works as well as tocilizu…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New imaging methods could transform PMR diagnosis
Diagnosis OngoingThis study explores whether ultrasound and PET/CT scans can more accurately diagnose and monitor polymyalgia rheumatica (PMR), a condition causing muscle pain and inflammation. Researchers will follow 98 adults over 50 suspected of having PMR, using imaging at key points during t…
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Kresten Krarup Keller • Aim: Diagnosis
Last updated Jun 11, 2026 12:11 UTC